There are reports of euglycemic diabetic ketoacidosis in T2DM patients using SGLT2 inhibitors [19,20,21,22], with approximately 0.1% overall incidence [23], especially in patients with lower body mass index and decreased glycogen stores [24]. This evidence concerns the gene SLC5A2 and diabetic ketoacidosis.